OSA and Liver Disease

by | Apr 7, 2026 | Blog | 0 comments

Here we summarize “Association between metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea: a nationwide retrospective cohort study” from Scientific Reports (Nature Portfolio), March 2026.

🎯 Objective

The study examined whether metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of developing obstructive sleep apnea (OSA) at a population level.

📊 Methods

  • Large nationwide cohort of ~265,000 Korean adults ≥40 years
  • Participants grouped based on:
    • Presence of fatty liver (via fatty liver index)
    • Cardiometabolic risk factors (e.g., obesity, diabetes)
    • Alcohol intake
  • Followed over time to assess new onset (incident) OSA

🔑 Key findings

  1. MASLD is associated with higher risk of OSA
    • Individuals with MASLD had a significantly increased risk of developing OSA compared to those without liver disease.
  2. Risk increases with metabolic dysfunction severity
    • The more cardiometabolic risk factors present, the higher the OSA risk.
  3. Alcohol-related phenotypes matter
    • People with MASLD plus alcohol intake (MetALD spectrum) also showed elevated OSA risk, suggesting combined metabolic + alcohol effects.
  4. Shared mechanisms likely drive the link
    • MASLD and OSA share:
      • Metabolic dysfunction (insulin resistance, obesity)
      • Inflammation
      • Possibly intermittent hypoxia effects
    • These overlapping pathways likely explain the association.

🧩 Interpretation

  • The relationship between MASLD and OSA is not just coincidental—it likely reflects shared pathophysiology.
  • MASLD may be a clinical marker to identify patients at higher OSA risk (and vice versa).

🏥 Clinical implications

  • Patients with MASLD should potentially be:
    • Screened for sleep apnea
  • Managing metabolic health (weight, diabetes, etc.) could help reduce risk of both conditions.
  • Supports a multisystem approach to cardiometabolic disease.

⚠️ Limitations

  • Observational (cannot prove causality)
  • Based on a Korean population → generalizability may vary
  • Uses surrogate markers (e.g., fatty liver index) rather than imaging/biopsy

🧠 Bottom line

This large cohort study shows that MASLD significantly increases the risk of developing obstructive sleep apnea, reinforcing that liver disease is part of a broader systemic metabolic disorder rather than an isolated condition.